Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 27
Views PDF: 21
DOI: https://doi.org/10.55046/vjrnm.01.71.2021
Issue
No. 01 (2021)
Section
Scientific research
How to Cite
Mai Hong , S., Le Quoc , K., Nguyen Thi , P., Nguyen Thi , N., Nguyen Thanh , H., Le Duy, . H., & Le Ngoc , H. (2022). 99mTc-maa spect/ct imaging for treatment response prediction after 90Y-radioembolization in HCC patients: comparison with post-treatment 90Y PET/CT. Vietnamese Journal of Radiology and Nuclear Medicine, 01, 38 - 45. https://doi.org/10.55046/vjrnm.01.71.2021

99mTc-maa spect/ct imaging for treatment response prediction after 90Y-radioembolization in HCC patients: comparison with post-treatment 90Y PET/CT

Mai Hong Son1,, Le Quoc Khanh2, Nguyen Thi Phương2, Nguyen Thi Nhung2, Nguyen Thanh Huong1, Le Duy Hung1, Le Ngoc Ha1
1 108 Hospital
2 108 hospital

Main Article Content

Abstract

90Y PET/CT imaging is performed after radioembolization to re-evaluate the resin microsphere distribution and estimate the absorbed radiation dose of target tumor. However, the distribution of 90Y resin microsphere on PET/CT was different from that of 99mTc-MAA simulation and additive role of PET/CT was not well established until now. The purpose of our
study is to validate the utility of 90Y PET/CT compared to SPECT/CT simulation in dosimetry and prediction of treatment response.
Material and method: Thirty-four consecutive HCC patients, intermediate and advanced stage who underwent 90Y resin microsphere transarterial embolization (TARE) were recruited in the study. Lung shunt fraction (LSF), tumor to-normal liver uptake ratio (TNr) and absorbed dose for target tumors were estimated on 99m Tc-MAA SPECT/CT and 90Y PET/CT. The patients were followed up after treatment within 3 months (2.8 mo ± 0.84) on contrast- enhanced CT to assess treatment response using
mRECIST criteria.
Results: The imaging characteristics of thrombosis uptake was better delineated on PET/CT imaging than SPECT/CT. The agreement and correlation of TNr on PET/CT and SPECT/CT were stronger. Dose delivery to tumor (Dtumor) threshold of 125 Gy estimated on 99mTc-MAA SPECT/CT was more accurate than PET/CT for prediction of treatment response after 90Y- adioembolization in HCC patients with sensitivity of 87.5% and specificity of 90%.
Conclusions: 99mTc-MAA SPECT/CT is superior to PET/CT to predict treatment response after 90Y resin microsphere treatment.

Article Details

References

1. Zhu RX, Seto W-K, Lai C-L, Yuen M-F. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut and liver. 2016;10(3):332-9.
2. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51(8):1206-12.
3. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393-406.
4. Gil‐Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez‐Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization‐induced liver disease. Hepatology (Baltimore, Md). 2013;57(3):1078-87.
5. Gates VL, Esmail AA, Marshall K, Spies S, Salem R. Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med. 2011;52(1):72-6.
6. Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9(3):335-48.
7. Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul J-L, Ardisson V, et al. Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39(5):872-80.
8. Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H, et al. Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nucl Med Commun. 2011;32(12):1245-55.
9. Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43:559-75.
10. Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. 2017;37(1):101-10.
11. Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53(4):559-66.